Core Insights - Defence Therapeutics Inc. will present new scientific data on its Accum® technology at the World ADC Conference in San Diego, highlighting its potential to enhance the efficacy of antibody-drug conjugates (ADCs) [1][2] Company Overview - Defence Therapeutics is a biotechnology company focused on drug delivery technologies, specifically developing next-generation ADC products using its proprietary Accum® platform [5] - The Accum® technology is designed to improve intracellular delivery and endosomal escape of therapeutic payloads, addressing limitations of current ADCs and enabling higher potency with reduced off-target toxicity [2][5] Scientific Findings - New results to be presented at the conference demonstrate Accum®'s ability to significantly improve the therapeutic index of ADCs, allowing for more efficient delivery of toxic payloads directly into cancer cells [2][3] - The Chief Scientific Officer of Defence Therapeutics expressed excitement about sharing these findings with the scientific community and advancing research towards next-generation targeted therapies [3] Conference Details - The World ADC Conference is a premier event for ADC innovation, featuring 1,400 industry attendees and over 170 world-class speakers, providing significant networking opportunities [4]

Core Insights - Defence Therapeutics Inc. is participating in CPHI Worldwide 2025, a major global pharmaceutical trade fair in Frankfurt, Germany from October 28-30, 2025 [1][2] Company Overview - Defence Therapeutics is a clinical-stage biotechnology company focused on developing next-generation antibody-drug conjugates (ADCs) using its proprietary ACCUM® technology, which enhances the precision delivery of ADCs to target cells, thereby increasing efficacy against cancer [6] Event Participation - The company aims to engage with potential partners across the biopharma value chain and connect with the global pharmaceutical community to learn about the latest trends in pharmaceutical manufacturing [2] - Defence Therapeutics is hosting a Meet & Greet event on October 29, 2025, from 4:30-6:30 PM at the Kimpton Hotel in Frankfurt, providing an informal setting for networking and exploring partnership opportunities [3][4] CPHI Overview - CPHI is a leading global pharmaceutical trade show expected to attract over 62,000 visitors and around 2,400 exhibiting companies in 2025, featuring more than 180 international speakers [5]

Core Insights - Defence Therapeutics Inc. has appointed Dr. Mark Lambermon as Head of Quality and Operations, bringing over 20 years of experience in pharmaceutical R&D and biotech innovation [1][2] - Dr. Lambermon's expertise will be crucial for the company's regulatory readiness and operational excellence as it advances its drug delivery technologies [3] - The company has granted Dr. Lambermon 100,000 incentive stock options, exercisable at $0.80 per share for three years [4] Company Overview - Defence Therapeutics is a clinical-stage biotechnology company focused on developing next-generation antibody-drug conjugates (ADCs) using its proprietary ACCUM® technology, which enhances the precision delivery of ADCs to target cells [5]

Core Insights - Defence Therapeutics Inc. is advancing its Accum® platform, which enhances the delivery of antibody-drug conjugates (ADCs) for cancer treatment, potentially transforming precision oncology [1][4][5] Company Overview - Defence Therapeutics is a clinical-stage biotechnology company focused on developing next-generation ADC products using its proprietary Accum® technology, which allows for precision delivery of ADCs to target cells [9] Technology and Innovation - The Accum® platform provides "laser-guided precision" in delivering drugs inside cancer cells, improving payload efficiency and reducing toxic side effects [2][3] - The analogy used illustrates that while traditional methods send many soldiers (drugs) to target a cancer cell, Accum® allows for a more effective approach with fewer drugs achieving the desired effect [3] Market Potential - ADCs are among the most effective anti-cancer drugs, but their use has been limited due to dose-limiting toxicity; Accum® may enable their application as first-line therapies [3][4] - Defence plans to partner with existing ADC developers and expand the applications of Accum® to novel therapies, indicating a strong near-term revenue outlook [4][5] Intellectual Property Strategy - The company employs a "picket fence" approach to protect its intellectual property portfolio globally, covering multiple aspects of the delivery platform [4]

Core Insights - Defence Therapeutics Inc. has appointed Dr. Amie Phinney to its Board of Directors, effective immediately, to enhance governance and long-term value creation as the company advances its drug-delivery platform [1][2][3] Group 1: Leadership Changes - Dr. Phinney previously served as a Strategy and Business Advisor and will now play a crucial role on the Board, contributing to strategic priorities and governance [2][3] - The CEO of Defence Therapeutics, Sébastien Plouffe, emphasized Dr. Phinney's significant impact on the company's strategic direction and her valuable experience in global pharma and biotech [3] Group 2: Incentives and Compensation - The company has granted Dr. Phinney 100,000 incentive stock options, which are vested immediately and exercisable at a price of $0.75 per share for three years [4] Group 3: Company Overview - Defence Therapeutics is a clinical-stage biotechnology company focused on developing next-generation antibody-drug conjugates (ADCs) using its proprietary ACCUM® technology, which allows for precision delivery to target cells, enhancing efficacy against cancer [5]

Group 1 - Defence Therapeutics Inc. has successfully closed a non-brokered private placement of debenture units, raising a total of $2,000,000 [1][5] - Each debenture unit consists of one $1,000 principal amount 8.0% convertible debenture and 1,666 common share purchase warrants [1][2] - The debentures have a maturity date of September 15, 2027, and are convertible into common shares at a price of $0.60 per share [2][3] Group 2 - The company paid a total of $160,000 in cash finder's fees and issued 266,667 finder's warrants, which are also exercisable at $0.75 per share [4] - The net proceeds from the offering will be used to advance the company's science programs and for general working capital [5] - All securities issued are subject to a statutory hold period of four months plus a day from their date of issue [5] Group 3 - Defence Therapeutics is a clinical-stage biotechnology company focused on developing next-generation antibody-drug conjugates (ADCs) using its proprietary ACCUM® technology [7]

Company Overview - Defence Therapeutics Inc. is a clinical-stage biotechnology company focused on drug delivery technologies, particularly in developing next-generation antibody-drug conjugates (ADCs) using its proprietary ACCUM® technology, which enhances the precision delivery of ADCs to target cells, thereby increasing efficacy against cancer [5]. Leadership Appointment - Dr. Amie Phinney has been appointed as the Strategy & Business Advisor to guide Defence Therapeutics in its next phase of growth, effective immediately [1]. - Dr. Phinney brings over 20 years of experience in life sciences commercialization, having held significant roles in pharmaceutical R&D and biotech innovation at companies like Abbott and AbbVie [2][3]. Strategic Vision - The company is at a pivotal point, with its scientific advancements opening new transformative opportunities. Dr. Phinney's expertise in both scientific and strategic leadership is expected to help the company capture this momentum for sustainable growth [4]. - Dr. Phinney expressed enthusiasm about joining Defence Therapeutics, highlighting the potential of the company's science to transform the field of antibody-delivered therapeutics and her commitment to building a roadmap for innovation [4].

Core Viewpoint - Defence Therapeutics Inc. is conducting a non-brokered private placement of debenture units to raise up to $1,200,000, aimed at enhancing its drug delivery technologies [1][2]. Financing Details - The offering consists of debenture units priced at $1,000 each, with a total gross proceeds target of $1,200,000 [1]. - Each unit includes one $1,000 principal amount of an 8.0% convertible debenture and 1,666 common share purchase warrants [1][2]. - The debentures will bear an interest rate of 8.0% per annum and will mature two years from the issue date [2]. - The principal amount of each debenture is convertible into common shares at a conversion price of $0.60 per share [2]. - Accrued interest can be paid annually in shares at the conversion price or in cash at the company's discretion [2]. Warrant Details - Each warrant allows the holder to acquire one common share at an exercise price of $0.75 for a period of two years from the issue date [3]. Regulatory and Compliance Information - All securities issued will be subject to a statutory hold period of four months and one day following the closing date [4]. - The completion of the offering is contingent upon receiving all necessary regulatory approvals [4]. - The company may pay a finder's fee to eligible arm's length finders in accordance with Canadian Securities Exchange policies [4]. Company Overview - Defence Therapeutics is a clinical-stage biotechnology company focused on developing next-generation antibody-drug conjugates (ADCs) using its proprietary ACCUM® technology, which enhances the precision delivery of ADCs to target cells, thereby increasing efficacy against cancer [6].

Core Insights - Defence Therapeutics Inc. is advancing its ADC and Radiopharma programs, focusing on collaborations and preclinical studies for cancer therapies using its Accum® technology [1][2][3] ADC Program - Defence's Accum®-based ADCs show improved intracellular delivery and cytotoxic activity in various preclinical cancer models compared to traditional ADCs [2] - The company is optimizing additional Accum®-based ADCs to enhance their value and attract potential licensing and co-development opportunities with Pharmaceuticals and Biotech companies [2] Radiopharmaceutical Program - The Radiopharma program is enhancing Accum® radiolabelling through studies conducted by Canadian Nuclear Laboratories, focusing on biodistribution, pharmacokinetics, and therapeutic potency [3] - The application of Accum® technology in the radiopharmaceuticals sector is expected to be transformative [3] Market Outlook - The global ADC market is projected to grow from USD 13.51 billion in 2025 to USD 29.9 billion by 2034, with a CAGR of 9.23% from 2024 to 2034 [4] - The global radiopharmaceutical market is expected to reach USD 16.87 billion by 2033, growing at a CAGR of 9.9% during 2025-2033 [4] Future Developments - The company plans to announce key results and partnership details as they become available, while continuing its studies in Canada and expanding its presence to the US [5] - Defence Therapeutics is a clinical-stage biotechnology company focused on developing next-generation ADC products using its proprietary Accum® technology [6]

Core Insights - Defence Therapeutics Inc. has received a Notice of Allowance from the USPTO for its U.S. patent application covering next-generation antibody-drug conjugate (ADC) technology, which includes broad composition-of-matter claims for therapeutically active ADCs [1][2] - The allowed patent application (no. 18/351,291) will potentially grant the company market exclusivity for its proprietary second-generation Accum®-based ADCs until 2043 [2][4] - The company has an established patent portfolio for its Accum® technology, with granted patents in the U.S., Japan, Australia, and Israel, and pending applications in Canada and Europe [3][4] Company Overview - Defence Therapeutics is a clinical-stage biotechnology company focused on developing next-generation ADC products using its proprietary Accum® technology, which enhances the precision delivery of ADCs to target cells [5] - The Accum® technology aims to increase the efficacy and potency of cancer treatments [5]